Obesity, ASCVD and PCSK9 Inhibition: What FOURIER Really Shows
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:
”Obesity, ASCVD and PCSK9 Inhibition: What FOURIER Really Shows
Obesity = higher cardiovascular risk. In the placebo arm, every +5 BMI units above 30 kg/m² increased MACE risk by 11%.
Benefit of evolocumab grows as BMI increases.
•BMI <30: 11% RRR, ARR 1.4%
•BMI 30–34.9: 14% RRR, ARR 1.8%
•BMI ≥35: 29% RRR, ARR 5.7%, NNT = 17 at 3 years
LDL-C lowering remains equally powerful across all BMI categories (≈–56% to –61%). Obesity didn’t blunt the lipid response.
Inflammation amplifies risk. Highest MACE rates occurred in patients with both obesity and elevated hsCRP (>3 mg/L) – and this group also derived the largest benefit from evolocumab.
Key insight: Obesity appears to create an “atherogenic + inflammatory” residual-risk phenotype that is highly modifiable with intensive LDL-C lowering.
Clinical message: For ASCVD patients with obesity – particularly those with class 2–3 obesity or high hsCRP – PCSK9 inhibition is not optional; it’s essential.
Open access.”
Title: Obesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition: A Prespecified Analysis From FOURIER
Authors: Yu Mi Kang, Robert P. Giugliano, Anthony C. Keech, J. Antonio G. López, Maria Laura Monsalvo, E. Magnus Ohman, Xinhui Ran, Sabina A. Murphy, Marc S. Sabatine, and Michelle L. O’Donoghue
Stay updated with Hemostasis today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy